72 related articles for article (PubMed ID: 7566165)
1. Immunology. Ways around rejection.
Vaux DL
Nature; 1995 Oct; 377(6550):576-7. PubMed ID: 7566165
[No Abstract] [Full Text] [Related]
2. A role for CD95 ligand in preventing graft rejection.
Bellgrau D; Gold D; Selawry H; Moore J; Franzusoff A; Duke RC
Nature; 1995 Oct; 377(6550):630-2. PubMed ID: 7566174
[TBL] [Abstract][Full Text] [Related]
3. CD95 ligand in graft rejection.
Yagita H; Seino K; Kayagaki N; Okumura K
Nature; 1996 Feb; 379(6567):682. PubMed ID: 8602212
[No Abstract] [Full Text] [Related]
4. Synergistic effects on the inhibition of human CD8+ cytotoxic T lymphocytes-mediated killing against xenograft cells by coexpression of membrane-bound Human FasL and decoy Fas antigen.
Tanemura M; Kawamoto K; Ito T; Uchikoshi F; Shimada K; Nishida T; Matsuda H
Transplant Proc; 2005 Dec; 37(10):4607-9. PubMed ID: 16387181
[TBL] [Abstract][Full Text] [Related]
5. Rejection of Fas ligand-expressing grafts.
Seino K; Kayagaki N; Fukao K; Okumura K; Yagita H
Transplant Proc; 1997; 29(1-2):1092-3. PubMed ID: 9123215
[No Abstract] [Full Text] [Related]
6. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival.
Stuart PM; Griffith TS; Usui N; Pepose J; Yu X; Ferguson TA
J Clin Invest; 1997 Feb; 99(3):396-402. PubMed ID: 9022072
[TBL] [Abstract][Full Text] [Related]
7. The role of Fas ligand as an effector molecule in corneal graft rejection.
Stuart PM; Yin X; Plambeck S; Pan F; Ferguson TA
Eur J Immunol; 2005 Sep; 35(9):2591-7. PubMed ID: 16114107
[TBL] [Abstract][Full Text] [Related]
8. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
[TBL] [Abstract][Full Text] [Related]
9. Accelerated rejection of Fas ligand-expressing heart grafts.
Takeuchi T; Ueki T; Nishimatsu H; Kajiwara T; Ishida T; Jishage K; Ueda O; Suzuki H; Li B; Moriyama N; Kitamura T
J Immunol; 1999 Jan; 162(1):518-22. PubMed ID: 9886428
[TBL] [Abstract][Full Text] [Related]
10. [Fas, fas ligand, immune tolerance, and cancer: implications in cancer of the colon].
Berger A; Piqueras B; Pages F; Tartour E; Cugnenc PH; Fridman WH
Bull Cancer; 1998 Feb; 85(2):129-33. PubMed ID: 9752329
[TBL] [Abstract][Full Text] [Related]
11. In vitro prevention of cell-mediated xeno-graft rejection via the Fas/FasL-pathway in CrmA-transducted porcine kidney cells.
Fujino M; Li XK; Suda T; Hashimoto M; Okabe K; Yaginuma H; Mikoshiba K; Guo L; Okuyama T; Enosawa S; Amemiya H; Amano T; Suzuki S
Xenotransplantation; 2001 May; 8(2):115-24. PubMed ID: 11328582
[TBL] [Abstract][Full Text] [Related]
12. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice.
Le Moine A; Surquin M; Demoor FX; Noël JC; Nahori MA; Pretolani M; Flamand V; Braun MY; Goldman M; Abramowicz D
J Immunol; 1999 Oct; 163(7):3778-84. PubMed ID: 10490975
[TBL] [Abstract][Full Text] [Related]
13. Immunology and immunopathology of male genital tract. Preface.
Lenzi A
Hum Reprod Update; 2001; 7(5):443. PubMed ID: 11556489
[No Abstract] [Full Text] [Related]
14. [The CD95/CD95L system as target for modulation of allogeneic immune responses].
Schwinzer R; Dulat H; Kyas U; Wonigeit K
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):655-8. PubMed ID: 14518336
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hepatocyte transplantation: contribution of Fas-Fas ligand interaction to allogeneic hepatocyte rejection.
Kawahara T; Yagita H; Kasai S; Sawa M; Kato K; Okumura K; Futagawa S; Mito M
J Gastroenterol Hepatol; 1998 Sep; 13 Suppl():S119-23. PubMed ID: 9792045
[TBL] [Abstract][Full Text] [Related]
16. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice.
Baker MB; Podack ER; Levy RB
Biol Blood Marrow Transplant; 1995 Dec; 1(2):69-73. PubMed ID: 9118294
[TBL] [Abstract][Full Text] [Related]
17. Transplantation of cells and tissues expressing Fas ligand.
Duke RC; Newell E; Schleicher M; Meech S; Bellgrau D
Transplant Proc; 1999 May; 31(3):1479-81. PubMed ID: 10330975
[No Abstract] [Full Text] [Related]
18. [CD95 (APO-1/Fas) and CD95-ligand (CD95L). Implications of these apoptosis mediating receptor/ligand systems in the pathogenesis of autoimmune diseases].
Möller P; von Reyher U; Leithäuser F; Sträter J
Verh Dtsch Ges Pathol; 1996; 80():12-20. PubMed ID: 9064994
[TBL] [Abstract][Full Text] [Related]
19. The CD95 system and the death of a lymphocyte.
Matiba B; Mariani SM; Krammer PH
Semin Immunol; 1997 Feb; 9(1):59-68. PubMed ID: 9106308
[TBL] [Abstract][Full Text] [Related]
20. Fas counter-attack--the best form of tumor defense?
O'Connell J; Bennett MW; O'Sullivan GC; Collins JK; Shanahan F
Nat Med; 1999 Mar; 5(3):267-8. PubMed ID: 10086376
[No Abstract] [Full Text] [Related]
[Next] [New Search]
